SARS-CoV-2 main proteases inhibitors (A2A Pharmaceuticals)

N/A

Report date: 2022/11/27 16:44:49
NME

Base Information

Drug NameSARS-CoV-2 main proteases inhibitors (A2A Pharmaceuticals)
Drug Alias NameSARS-CoV-2 MPro (A2A Pharmaceuticals)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtease inhibitors
TargetsProtease
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesA2A Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesA2A Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A